Ranolazine Unveiled: Rediscovering an Old Solution in a New Light-Reference-Cited by-同舟云学术

Ranolazine Unveiled: Rediscovering an Old Solution in a New Light

Published:2024-08-23 Issue:17 Volume:13 Page:4985
ISSN:2077-0383
Container-title:Journal of Clinical Medicine
language:en
Short-container-title:JCM

Author:

De Santis Giulia Azzurra¹,De Ferrari Tommaso¹,Parisi Francesca²^ORCID,Franzino Marco³^ORCID,Molinero Agustin Ezequiel¹,Di Carlo Alessandro¹,Pistelli Lorenzo⁴^ORCID,Vetta Giampaolo⁵^ORCID,Parlavecchio Antonio¹^ORCID,Torre Marco⁴^ORCID,Parollo Matteo⁴,Mansi Giacomo⁴,Tamborrino Pietro Paolo⁴,Canu Antonio⁴,Grifoni Gino⁴,Segreti Luca⁴,Di Cori Andrea⁴^ORCID,Viani Stefano Marco⁴,Zucchelli Giulio⁴

Affiliation:

1. Cardiology Unit, Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy

2. Clinical Cardiology and Heart Failure Unit, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), 90127 Palermo, Italy

3. S.C. Cardiologia, Ospedale Sant’Andrea, 13100 Vercelli, Italy

4. Second Division of Cardiology, Cardio-Thoracic and Vascular Department, Pisa University Hospital, 56124 Pisa, Italy

5. Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, European Reference Networks Guard-Heart, 1050 Brussels, Belgium

Abstract

Ranolazine is an anti-anginal medication that has demonstrated antiarrhythmic properties by inhibiting both late sodium and potassium currents. Studies have shown promising results for ranolazine in treating both atrial fibrillation and ventricular arrhythmias, particularly when used in combination with other medications. This review explores ranolazine’s mechanisms of action and its potential role in cardiac arrhythmias treatment in light of previous clinical studies.

Publisher

MDPI AG

Link

https://www.mdpi.com/2077-0383/13/17/4985/pdf

Reference56 articles.

1. Ranolazine (RS-43285): A preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium;Jain;Eur. J. Clin. Pharmacol.,1990

2. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC);Knuuti;Eur. Heart J.,2020

3. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients with Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines;Virani;Circulation,2023

4. Ranolazine: A Contemporary Review;Sedlak;J. Am. Heart Assoc.,2016

5. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions;Chaitman;Circulation,2006